Inhibrx, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Inhibrx, Inc. | INBX - NASDAQ |
$16.00-$18.00 | $17.00 | $22.10 | 7 million | 8/19/2020 |
| Jefferies, Evercore ISI, Credit Suisse | ||||||
Co-Manager(s): LifeSci Capital | ||||||
| Health Care | ||||||
Filing(s): 1st Filed 2019-06-03 Filed 2020-07-28 Terms Added 2020-08-12 | ||||||
Inhibrx, Inc. Quote & Chart - Click for current quote - INBX
IPO Boutique aggregates information on public companies and private companies, such as "INBX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Inhibrx, Inc. (adapted from Inhibrx, Inc. prospectus):
They are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using our protein engineering expertise and proprietary single domain antibody, or sdAb, platform.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using our protein engineering expertise and proprietary single domain antibody, or sdAb, platform.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "INBX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.